Kainos Medicine KRX:284620KOSDAQ
카이노스메드 · Korean news coverage and regulatory filings, organized.
In Q3 2026, Kainos Medicine reported revenue of ₩402m, up 24.8% year on year, and an operating loss of ₩582m. Kainos Medicine (카이노스메드) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals 4 quarters of losses Screener
Kainos Medicine today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates Kainos Medicine stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
Kainos Medicine quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩402m | +24.8% | −₩582m margin −144.8% | −₩928m |
| Q2 2026 | ₩408m | +131.2% | −₩1.1bn margin −258.1% | −₩1.3bn |
| Q1 2026 | ₩370m | +0.4% | −₩1.0bn margin −273.2% | −₩1.3bn |
| Q4 2025 derived | ₩304m | +326.3% | −₩2.3bn | −₩1.9bn |
| Q3 2025 | ₩322m | +58.2% | −₩1.5bn | −₩1.8bn |
| Q2 2025 | ₩176m | -0.1% | −₩945m | −₩1.9bn |
| Q1 2025 | ₩369m | +165.9% | −₩1.7bn | −₩2.2bn |
| Q4 2024 derived | ₩71m | -29.4% | −₩4.2bn | −₩4.2bn |
Kainos Medicine ranks #1659 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kainos Medicine top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.